Structural evidence of anti-atherogenic microRNAs

被引:12
|
作者
Virtue, Anthony [1 ,2 ]
Mai, Jietang [1 ,2 ]
Yin, Ying [1 ,2 ]
Meng, Shu [1 ,2 ]
Tran, Tran [1 ,2 ]
Jiang, Xiaohua [1 ,2 ]
Wang, Hong [1 ,2 ]
Yang, Xiao-Feng [1 ,2 ]
机构
[1] Temple Univ, Sch Med, Dept Pharmacol, Philadelphia, PA 19140 USA
[2] Temple Univ, Sch Med, Cardiovasc Res Ctr, Philadelphia, PA 19140 USA
来源
基金
美国国家卫生研究院;
关键词
microRNAs; mRNA stability; inflammatory genes; atherosclerosis; vascular inflammation; T-CELLS; VASCULAR INFLAMMATION; MYOCARDIAL-INFARCTION; ATHEROSCLEROSIS; EXPRESSION; TARGETS; SIGNATURE; SENSITIVITY; APOPTOSIS; ANTISENSE;
D O I
10.2741/3901
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Our research attempted to address two important questions - how microRNAs modulate atherogenic inflammatory genes from a panoramic viewpoint and whether their augmented expression results from reduced microRNAs suppression. To resolve these knowledge gaps, we employed a novel database mining technique in conjunction with statistical analysis criteria established from experimentally verified microRNAs. We found that the expression of 33 inflammatory genes up-regulated in atherosclerotic lesions contain structural features in the 3'UTR of their mRNAs for potential microRNAs regulation. Additionally, the binding features governing the interactions between the microRNAs and the inflammatory gene mRNA were statistically identical to the features of experimentally verified microRNAs. Furthermore, 21 of the 33 inflammatory genes (64%) were targeted by highly expressed microRNAs and 10 of these (48%) were targeted by a single microRNA, suggesting microRNA regulation specificity. Supplementing our findings, 7 out of the 20 unique microRNAs (35%) were previously confirmed to be down-regulated when treated with pro-atherogenic factors. These results indicate a critical role of anti-inflammatory microRNAs in suppressing pro-atherogenic inflammatory gene expression.
引用
收藏
页码:3133 / 3145
页数:13
相关论文
共 50 条
  • [41] Anti-atherogenic properties of vitamin E, aspirin, and their combination
    Chai, Sheau C.
    Foley, Elizabeth M.
    Arjmandi, Bahram H.
    PLOS ONE, 2018, 13 (10):
  • [42] Anti-Atherogenic Properties of Extra Virgin Olive Oil
    Yanai, Hidekatsu
    JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2019, 9 (1-2) : 1 - 2
  • [43] Anti-atherogenic effects of fibrates in type 2 diabetes
    Barter, P
    CURRENT CONTROLLED TRIALS IN CARDIOVASCULAR MEDICINE, 2001, 2 (05): : 218 - 220
  • [44] Evaluation of the anti-atherogenic potential of chrysin in Wistar rats
    Anandhi, Ramalingam
    Thomas, Philip A.
    Geraldine, Pitchairaj
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2014, 385 (1-2) : 103 - 113
  • [45] PROGNOSTIC IMPLICATIONS OF ATHEROGENIC/ANTI-ATHEROGENIC LIPID RATIOS IN AN ETHNICALLY DIVERSE POPULATION
    Manickam, Palaniappan
    Rathod, Ankit
    Badheka, Apurva
    Veeranna, Vikas
    Hari, Pawan
    Niraj, Ashutosh
    Jacob, Sony
    Afonso, Luis
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (10)
  • [46] Antioxidant and anti-atherogenic activities of olive oil phenolics
    Turner, R
    Etienne, N
    Alonso, MG
    de Pascual-Teresa, S
    Minihane, AM
    Weinberg, PD
    Rimbach, G
    INTERNATIONAL JOURNAL FOR VITAMIN AND NUTRITION RESEARCH, 2005, 75 (01) : 61 - 70
  • [47] Evaluation of the anti-atherogenic potential of chrysin in Wistar rats
    Ramalingam Anandhi
    Philip A. Thomas
    Pitchairaj Geraldine
    Molecular and Cellular Biochemistry, 2014, 385 : 103 - 113
  • [48] MOLECULAR MECHANISMS UNDERLYING THE ANTI-ATHEROGENIC ACTIONS OF NUTRACEUTICALS
    Moss, J. W. E.
    Williams, J. O.
    Gallagher, H.
    Al-Ahmadi, W.
    Ismail, A.
    O'Morain, V.
    Ramji, D. P.
    CARDIOLOGY, 2018, 140 : 17 - 17
  • [49] Local inhibition of neutral endopeptidase 24.11 is anti-atherogenic
    Barber, MN
    Kanagasundaram, M
    Woods, RL
    FASEB JOURNAL, 2004, 18 (04): : A634 - A634
  • [50] Anti-atherogenic effects of high density lipoproteins: Mechanisms
    Barter, PJ
    Rye, KA
    Clay, MA
    Ashby, D
    Baker, P
    Xia, P
    Gamble, JR
    Vadas, MA
    ATHEROSCLEROSIS, 1997, 134 (1-2) : 285 - 285